Core Viewpoint - A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. for allegedly misleading investors regarding the safety and efficacy of its drug DCCR (VYKAT™ XR) [1][4]. Group 1: Lawsuit Details - The lawsuit seeks to represent investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025 [1][3]. - The lawsuit was triggered by a disappointing report on November 5, 2025, regarding DCCR, which led to a 26% drop in the company's share price [2][4]. Group 2: Allegations Against Soleno - The litigation focuses on Soleno's statements about DCCR's safety, efficacy, and commercial prospects, which were claimed to be misrepresented [4]. - The lawsuit alleges that Soleno downplayed significant safety concerns related to DCCR, including issues of excess fluid retention in clinical trial participants [4]. - It is claimed that DCCR had materially lower commercial viability than disclosed, with undisclosed risks of significant adverse events post-launch [4]. Group 3: Market Reaction and Investor Sentiment - The market reaction began on August 15, 2025, when Scorpion Capital raised concerns about Soleno's disclosures, leading to a nearly 40% decline in share price by November 5, 2025 [5]. - Scorpion Capital highlighted reports of children hospitalized for potential heart failure after using VYKAT™ XR, raising doubts about the drug's market viability [5]. - Soleno's management acknowledged a disruption in their launch trajectory during the Q3 2025 earnings call, attributing it to the negative impact of the short seller report [5].

Core Viewpoint - A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. for allegedly misleading investors regarding the safety and efficacy of its drug DCCR (VYKAT™ XR) intended for treating hyperphagia associated with Prader-Willi Syndrome [1][4]. Company Overview - Soleno Therapeutics, Inc. is facing legal scrutiny following a significant drop in its stock price after a disappointing report on DCCR, which led to a 26% selloff on November 5, 2025 [2][4]. - The lawsuit claims that Soleno made repeated false statements about the safety and commercial prospects of DCCR, which included assurances of a successful launch that did not align with the actual market performance [4]. Legal Proceedings - The class action lawsuit seeks to represent investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025, with a lead plaintiff deadline set for May 5, 2026 [1][3]. - Hagens Berman, a national shareholders rights firm, is investigating whether Soleno violated federal securities laws and is encouraging affected investors to come forward [3][6]. Market Reaction - The market reacted negatively to the news about DCCR, with Soleno's stock price falling nearly 40% from August 14, 2025, to November 5, 2025, following critical reports from activist short seller Scorpion Capital [5]. - Scorpion Capital raised concerns about the drug's safety, citing reports of children hospitalized for potential heart failure after using VYKAT™ XR, and questioned the integrity of Soleno's clinical trial data [5]. Financial Implications - The lawsuit highlights that DCCR may have lower commercial viability than previously disclosed, with significant undisclosed risks regarding adverse events post-launch [4]. - The investigation by Hagens Berman aims to determine the extent of potential misrepresentation by Soleno regarding the drug's commercial prospects [6].